Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

被引：0
|
作者：
Rizzo, Alessandro [1 ]
Frega, Giorgio [2 ]
Ricci, Angela Dalia [1 ]
Palloni, Andrea [1 ]
Tavolari, Simona [3 ]
Brandi, Giovanni [2 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Policlin S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[3] Univ Bologna, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors in the peri-operative setting in renal cell carcinoma: A meta-analysis of the randomized clinical trials.
    Esteban Villarrubia, Jorge
    Carril-Ajuria, Lucia
    Carretero-Gonzalez, Alberto
    Romero Ferreiro, Carmen
    Alvarez, Pablo
    Ruiz-Vico, Maria
    Castellano, Daniel
    de Velasco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [42] Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.
    Lee, Kyung-Hun
    Lee, Dae-Won
    Jang, Myoung-Jin
    Kim, Tae-Yong
    Han, Sae-Won
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Tae-You
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Transarterial chemoembolization in patients with unresectable hepatocellular carcinoma:: A meta-analysis of randomized controlled trials.
    Schepis, F
    Orlando, A
    Albanese, M
    Shahied, L
    Trevisani, F
    Andreone, P
    Craxi, A
    Cottone, M
    Cammà, C
    HEPATOLOGY, 2001, 34 (04) : 178A - 178A
  • [44] Patients with sarcomatoid renal cell carcinoma-re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
    Iacovelli, Roberto
    Ciccarese, Chiara
    Bria, Emilio
    Bracarda, Sergio
    Porta, Camillo
    Procopio, Giuseppe
    Tortora, Giampaolo
    EUROPEAN JOURNAL OF CANCER, 2020, 136 : 195 - 203
  • [45] Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
    Tun, Aung
    Thein, Wai Lin
    Elfiky, Aymen
    Gasperino, James
    Guevara, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [46] Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
    Thein, Wai Lin
    Tun, Aung
    Thein, Kyaw Zin
    Guevara, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Efficacy of treatment regimens for advanced hepatocellular carcinoma A network meta-analysis of randomized controlled trials
    Chen, Qi-Feng
    Wu, Pei-Hong
    Huang, Tao
    Shen, Lu-Jun
    Huang, Zi-Lin
    Li, Wang
    MEDICINE, 2019, 98 (40)
  • [48] Efficacy and safety profile of sunitinib as a first line treatment for advanced/metastatic clear-cell renal cell carcinoma: Pooled analysis of randomized controlled trials.
    Haykal, Tarek
    Samji, Varun
    Zayed, Yazan
    Al-Dulaimi, Ragheed
    Gakhal, Inderdeep
    Bala, Areeg
    Sotzen, Jason
    Ghamrawi, Ranine
    Katato, Khalil
    Danish, Rizwan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
    Chen, Hsiao-Ling
    Chan, Vinson Wai-Shun
    Tu, Yu-Kang
    Chan, Erica On-Ting
    Chang, Hsiu-Mei
    Juan, Yung-Shun
    Teoh, Jeremy Yuen-Chun
    Lee, Hsiang Ying
    CANCERS, 2021, 13 (06)
  • [50] Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
    Wang, Hui
    Wang, Hefang
    Yu, Zhichong
    Liu, Honghao
    ONCOTARGETS AND THERAPY, 2018, 11 : 5195 - 5201
12345